Roy B. Tishler

Roy B. Tishler

Auto-generated profile, based on publicly available information

Roy B. Tishler

Dana-Farber Cancer Institute 4 Department of Radiation Oncology Boston, Massachusetts

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 June 2024 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
GHGlenn J. Hanna
Glenn J. Hanna
MDMichael J. Dennis
Michael J. Dennis
NSNicole Scarfo
Nicole Scarfo
MMMichelle S. Mullin
Michelle S. Mullin
RSRosh K.V. Sethi
Rosh K.V. Sethi
EREleni M. Rettig
Eleni M. Rettig
Purpose: Many patients with locoregionally advanced human papillomavirus–negative head and neck squamous cell carcinoma (HNSCC) relapse. ctDNA has the potential to identify minimal residual disease, but its clinical utility for virus-negative HNSCC is not well understood. Experimental Design: We retrospectively evaluated a personalized, commercial ctDNA assay (Signatera, Natera) during clinical care of patients treated for predominantly newly diagnosed human papillomavirus–negative HNSCC. Signatera utilizes 16-plex PCR from matched tumor and blood. Objectives were to understand ctDNA detectability and correlate changes posttreatment with disease outcomes. Results: Testing was successful in 100/116 (86%) patients (median age: 65 years, 68% male, 65% smokers); testing failed in 16 (14%) because of insufficient tissue. Oral cavity (55, 47%) tumors were most common; most had stage III to IV disease (82, 71%), whereas 17 (15%) had distant metastases. Pretreatment, 75/100 patients with successful testing (75%) had detectable ctDNA (range: 0.03–4049.69 mean tumor molecules/mL). No clinical features predicted ctDNA detectability or levels (multivariate analysis). At a median follow-up of 5.1 months (range: 0.2–15.1), 55 (55%) had >1 test result (range: 1–7; 194 samples). Of 55 patients, 17 (31%) remained ctDNA positive after starting treatment. Progression-free survival was significantly worse for patients who were ctDNA positive versus ctDNA negative posttreatment (HR, 7.33; 95% confidence interval, 3.12–17.2; P < 0.001); 1-year overall survival was 89.1% versus 100%, respectively (HR, 7.46; 95% confidence interval, 0.46–119.5; P = 0.155). Conclusions: Tumor-informed ctDNA testing is feasible in nonviral HNSCC. ctDNA positivity is an indicator of disease progression and associated with inferior survival. Further research is warranted to understand whether ctDNA may be leveraged to guide therapy in HNSCC.

23 December 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
EREleni M. Rettig
Eleni M. Rettig
JSJonathan D. Schoenfeld
Jonathan D. Schoenfeld
JMJulianna Miller
Julianna Miller
BSBethany Sargent
Bethany Sargent
ECEvan Carey
Evan Carey
GHGlenn J. Hanna
Glenn J. Hanna
Purpose: Observational studies suggest circulating tumor human papillomavirus (HPV) DNA may facilitate early detection of recurrent HPV-positive oropharynx cancer. We prospectively investigated whether biomarker-guided surveillance detects recurrence earlier than the standard-of-care methods. Patients and Methods: We enrolled patients evaluated for HPV-positive oropharynx cancer at a single center from November, 2020, to April, 2023, undergoing curative-intent treatment in a single-arm cohort study. Pretreatment plasma and/or tumor tissue were tested for tumor tissue–modified viral (TTMV) HPV DNA from HPV subtypes 16/18/31/33/35 using a droplet digital PCR–based commercial assay. Posttreatment plasma TTMV was assessed periodically. Detectable/indeterminate tests prompted imaging. The primary outcome was the proportion of recurrences first detected by TTMV. Results: Median follow-up was 23 months, with median six posttreatment TTMV tests for 155 subjects. Fifteen subjects (9%) experienced recurrence. Among these, six [40%, 95% confidence interval (CI) = 16%–68%] were “early true-positives,” for whom TTMV detection predated and prompted the imaging and clinical workup that diagnosed recurrence (median lead time = 132 days; range = 47–280). Another five subjects (33%) were “confirmatory true-positives,” for whom detectable TTMV confirmed suspicious standard-of-care imaging findings. Finally, four subjects (27%) with recurrence had undetectable TTMV at diagnosis (“false-negatives”). False-negatives had low or undetectable pretreatment TTMV, and 2/4 had non-HPV16 genotypes. Finally, three subjects had prolonged detectable TTMV without disease (“false-positives”); all had immunologic comorbidities. Overall, the sensitivity of TTMV for recurrence was 73% (95% CI = 45%–92%). Among 117 subjects with HPV16 and detectable pretreatment TTMV, sensitivity was higher (91%, 95% CI = 59%–100%). Conclusions: TTMV-guided surveillance facilitates early detection of many HPV-positive oropharynx cancer recurrences, with the highest sensitivity for HPV16 and detectable pretreatment TTMV. Clinical implementation should be carefully informed by the limitations described in this study. See related commentary by Califano, p. 1561

1 June 2020 in Oral Oncology
Verified
Journal Article
Closed access
AKAlec Kacew
Alec Kacew
EHEthan J. Harris
Ethan J. Harris
JLJochen H. Lorch
Jochen H. Lorch
JSJonathan D. Schoenfeld
Jonathan D. Schoenfeld
DMDanielle N. Margalit
Danielle N. Margalit
GHGlenn J. Hanna
Glenn J. Hanna

1 July 2006 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
RTRoy B. Tishler
Roy B. Tishler
MPMarshall R. Posner
Marshall R. Posner
CNCharles M. Norris
Charles M. Norris
AMAnand Mahadevan
Anand Mahadevan
CSChristopher Sullivan
Christopher Sullivan
RHRobert I. Haddad
Robert I. Haddad

1 November 2017 in The Oncologist
Verified
Journal Article
Open access
PDF file
ASAhmed Sultan
Ahmed Sultan
GHGlenn J. Hanna
Glenn J. Hanna
DMDanielle N. Margalit
Danielle N. Margalit
NCNicole Chau
Nicole Chau
LGLaura A. Goguen
Laura A. Goguen
HMHani Mawardi
Hani Mawardi
The Oncologist is committed to helping physicians excel in the constantly changing fields of oncology and hematology through the publication of timely reviews, original studies, and commentaries on important developments.

1 March 2020 in Advances in Radiation Oncology
Verified
Journal Article
Open access
DKDaniel W. Kim
Daniel W. Kim
GLGrace Lee
Grace Lee
MLMiranda B. Lam
Miranda B. Lam
EHEthan J. Harris
Ethan J. Harris
ALAllen C. Lam
Allen C. Lam
RTRoy B. Tishler
Roy B. Tishler